Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 152

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 152
---

an effort to bring our Depositary Share price into compliance with NASDAQ’s minimum bid price per share requirement, we effected
a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 400 Ordinary Shares per Depositary Share to
10,000 Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

On November 22, 2024, we held
the November GM, and our shareholders passed resolutions to (i) subdivide our Ordinary Shares of £0.001 nominal value each into
one ordinary share of £0.00005 nominal value and 19 C Deferred Shares of £0.00005 nominal value each, which became effective
on November 25, 2024 and (y) adopt new Articles of Association, which make consequential amendments to the existing articles of association
of the Company to reflect the November Subdivision. As is standard for deferred shares, each C Deferred Share has very limited rights
and is effectively valueless. The C Deferred Shares have the rights and restrictions as set out in the Articles of Association and do
not entitle the holder thereof to receive notice of or attend and vote at any general meeting of the Company or to receive a dividend
or other distribution.

Registered Direct Offering and Concurrent Private Placement

On
July 22, 2024, we completed the closing of the July 2024 Registered Direct Offering and the July 2024 Private Placement with certain Investors,
for the sale of (i) an aggregate of 202,032 Depositary Shares, and (ii) an aggregate of 11,157 pre-funded warrants exercisable for Depositary
Shares, or the July 2024 Pre-Funded Warrants, at a price per Depositary Share of $23.50, and a price per July 2024 Pre-Funded Warrant
of $23.4975. The aggregate gross proceeds to us were approximately $5.0 million, before deducting the placement agent’s fees and related offering expenses.

| 78 |

TheJuly
2024 Pre-Funded Warrants were sold, in lieu of Depositary Shares, to the Investors such that the Investors’ purchase of Depositary Shares in the Registered Direct Offering would not otherwise result in the Investor, together with their affiliates and certain related parties, beneficially owning more than 4.99% or 9.99% of our Ordinary Shares immediately following the consummation of the July 2024 Registered Direct Offering. EachJuly 2024 Pre-Funded